

Visible light. Part I: Properties and cutaneous effects of visible light



Evan Austin, BS,^{a,b} Amaris N. Geisler, BS,^c Julie Nguyen, MD,^{a,b} Indermeet Kohli, PhD,^d Iltefat Hamzavi, MD,^d Henry W. Lim, MD,^d and Jared Jagdeo, MD, MS^{a,b}
Brooklyn and New York, New York; and Detroit, Michigan

Learning objectives

After completing this learning activity, participants should be able to define visible light and classify it on the electromagnetic spectrum; distinguish visible light from UV and infrared radiation; list the types of visible light phototherapy; identify the clinical uses and limitations of visible light; discuss known effects of visible light on the skin; discuss safety of visible light; and describe the future directions of visible light and how its use can be translated to patient care.

Disclosures

Editors

The editors involved with this CME activity and all content validation/peer reviewers of the journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

Authors

Dr Lim is an investigator for Incyte, L'Oreal, Pfizer, and PCORI, has served as a consultant for Pierre Fabre, ISDIN, Ferndale, Beiersdorf, and La Roche-Posay, and has participated as a speaker in general educational session for La Roche-Posay, and Cantabria labs. Dr Kohli is an investigator (grant funding received by the institution) for Ferndale, Estee Lauder, L'Oreal, Unigen, Johnson and Johnson, Allergan, and Bayer and is a consultant (fee and equipment received by the institution) for Pfizer, Johnson and Johnson, and Bayer. Dr Jagdeo is a member of the GlobalMed Scientific advisory board and a consultant for UV Biotek. Iltefat Hamzavi is an investigator for Estee Lauder, Ferndale Laboratories, Galderma, Bayer, Loreal, Lencura, and Unigen. Amaris Geisler and Evan Austin have no conflicts of interest to declare.

Planners

The planners involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). The editorial and education staff involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

Approximately 50% of the sunlight reaching the Earth's surface is visible light (400-700 nm). Other sources of visible light include lasers, light-emitting diodes, and flash lamps. Photons from visible light are absorbed by photoreceptive chromophores (e.g., melanin, heme, and opsins), altering skin function by activating and imparting energy to chromophores. Additionally, visible light can penetrate the full thickness of the skin and induce pigmentation and erythema. Clinically, lasers and light devices are used to treat skin conditions by utilizing specific wavelengths and treatment parameters. Red and blue light from light-emitting diodes and intense pulsed light have been studied as antimicrobial and anti-inflammatory treatments for acne. Pulsed dye lasers are used to treat vascular lesions in adults and infants. Further research is necessary to determine the functional significance of visible light on skin health without confounding the influence of ultraviolet and infrared wavelengths. (J Am Acad Dermatol 2021;84:1219-31.)

Key words: chromophores; lasers; optical radiation; photobiomodulation; photodermatitis; phototherapy; porphyria; visible light.

From the Department of Dermatology, SUNY Downstate Medical Center, Brooklyn^a; Dermatology Service, VA New York Harbor Healthcare System, Brooklyn Campus, Brooklyn^b; CUNY School of Medicine, New York^c; and Department of Dermatology, Photomedicine and Photobiology Unit, Henry Ford Health System, Detroit.^d

Funding sources: Dr Jagdeo is supported by a National Institute of General Medical Sciences of the National Institutes of Health (NIH) award (K23GM1173090).

IRB approval status: Not applicable.

Accepted for publication February 19, 2021.

Reprints not available from the authors.

Correspondence to: Jared Jagdeo, MD, MS, Department of Dermatology, SUNY Downstate, 450 Clarkson Avenue, Brooklyn, NY 11203. E-mail: jjagdeo@gmail.com.

0190-9622/\$36.00

© 2021 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.

<https://doi.org/10.1016/j.jaad.2021.02.048>

Date of release: May 2021.

Expiration date: May 2024.



Scanning this QR code will direct you to the CME quiz in the American Academy of Dermatology's (AAD) online learning center where after taking the quiz and successfully passing it, you may claim 1 AMA PRA Category 1 credit. NOTE: You must have an AAD account and be signed in on your device in order to be directed to the CME quiz. If you do not have an AAD account, you will need to create one. To create an AAD account: go to the AAD's website: www.aad.org.

Abbreviations used:

BL:	blue light
COX:	cytochrome c oxidase
CPD:	cyclobutane pyrimidine dimer
EMR:	electromagnetic radiation
EUV:	extreme UV
IPL:	intense pulsed light
IR:	infrared
LED:	light-emitting diode
OPN:	opsin
PDL:	pulsed dye laser
PDT:	photodynamic therapy
PLE:	polymorphous light eruptions
PWS:	port wine stains
RL:	red light
RNS:	reactive nitrogen species
ROS:	reactive oxygen species
UV:	ultraviolet
UVR:	ultraviolet radiation
VL:	visible light

ELECTROMAGNETIC RADIATION

- Optical radiation includes ultraviolet, visible, and infrared radiation
- Most sunlight reaching the Earth's surface is visible or infrared

Electromagnetic radiation (EMR) includes gamma rays, X-rays, ultraviolet (UV), visible light (VL), infrared (IR), microwaves, and radio waves (Fig 1). Ultraviolet radiation (UVR), VL, and IR are considered optical radiation (10 nm-1 mm) and defined as "light" for clarity and convenience. The cutaneous effects of UVR and IR have been well studied and there have been recent advances in understanding the effect of VL on the skin.¹⁻¹⁰ VL is a narrow spectrum (400-700 nm) of EMR that the human eye can detect.³ VL accounts for ~50% of the solar radiation reaching Earth's surface and can be further divided by color and wavelength.^{3,11,12} UVR (10-400 nm) comprises ~5% of the solar radiation reaching the Earth's surface.^{11,13,14} Ultraviolet-C and extreme UV (EUV) are filtered by the atmosphere.^{11,13,14} IR (700 nm-1 mm) comprises the remaining 45% of the solar radiation that reaches Earth's surface.

PARAMETERS, DEVICES, AND SAFETY

- Natural and artificial sources emit VL
- Devices produce different forms of light based on operating principles

Parameters

Natural and artificial sources emit VL. Light exposure in a medical context can be described by specific terms and parameters (Table 1).¹⁵⁻²⁰

Devices

Multiple types of devices deliver VL as a therapeutic modality, including lasers, light-emitting diodes (LEDs), arc/flash lamps, halogen lamps, and fluorescent lights (Fig 2).³

Safety

Solar irradiance at the Earth's atmosphere is referred to as the solar constant (~136 mW/cm²).^{21,22} VL comprises ~53 mW/cm² of the solar constant.^{21,22} The solar irradiance at the Earth's surface (~100 mW/cm²) will vary depending on the latitude, time, and weather/atmospheric conditions.^{21,22} Commercially available VL sources used in dermatology practices may have power densities that exceed 100 mW/cm², such as lasers and LEDs.^{17,23} According to the regulatory standards of the United States (US) Occupational Safety and Health Administration, lasers in the VL domain can damage the retina; therefore, wavelength-specific safety goggles are recommended for VL procedures. US Food and Drug Administration regulations for skin photoprotection are based on minimal erythema dose and critical wavelengths. These are discussed in Part II of this CME program.

DEPTH OF PENETRATION

- Red light (625-700 nm) penetrates the skin deeper than does blue light (400-500 nm)
- Red light can penetrate the full thickness of the skin

Light propagation and penetration through the skin are dependent on reflection, scattering, and absorption.²⁴ Approximately 4% to 7% of VL is reflected by the skin surface, regardless of incident wavelength, pigmentation, or structure.^{24,25} Keratins, collagen, melanin, and hemoglobin are the primary skin molecules responsible for VL penetration via scattering and absorption.^{24,25} Zinc, ion-gated channels, NADH, bilirubin, and β -carotene also absorb and scatter VL.

Most skin scattering occurs when photons excite charged particles in filamentous proteins, which re-emit photons. Epidermal scattering may be greater than dermal scattering due to melanin in the epidermis.²⁴⁻²⁷ In the dermis, scattering occurs mainly in the direction of the incident beam because the diameters of collagen fibers are similar to those of VL wavelengths (i.e., Mie scattering), resulting in an enhanced depth of penetration.²⁴⁻²⁷

Chromophores, such as cytochrome c oxidase (COX), absorb specific light wavelengths, which excite electrons into a higher energy state. Subsequent activation of second messengers, including reactive oxygen species (ROS), adenosine




Fig 1. Electromagnetic radiation spectrum. UVR, VL, and IR are optical radiation. VL can be divided by color: blue/violet (400-500 nm), green (500-565 nm), yellow (565-590 nm), orange (590-625 nm), or red (625-700 nm). Similarly, UVR is separated into separate spectra: UVA (320-400 nm), UVB (290-320 nm), Ultraviolet-C (200-290 nm), and extreme (EUV; 10-120 nm). IR can be subdivided into infrared-A (near-IR; 700-1440 nm), IRB (mid-IR; 1440-3000 nm), and IRC (far-IR; 3000 nm-1 mm) wavelengths. Spectral boundaries are not discrete, and there is an overlap in the biologic effects between adjacent forms of EMR.

Table I. Definition of light parameters

Terminology	Definition	Standard unit
Wavelength	Distance between 2 peaks of a wave function	Meters
Irradiance (power density)	The power (energy/second) of light delivered to a unit of surface area	Watts/meter ²
Fluence (dose)	The amount of energy delivered to a unit of surface area over a given time (fluence = irradiance x time)	Joules/meter ²
Duration of exposure	The amount of time that the skin is exposed to light	Seconds
Pulse width	The length of time that a pulsed device delivers light (i.e., “flashes” in a repetitive mode)	Seconds
Beam width	The diameter of the beam; the edge of the beam is defined by having an irradiance of at least $1/e^2$ of maximum irradiance	Meters
Duty cycle	Percentage of time that the signal is active during 1 cycle	Percentage of time
Luminance	The intensity of light at the source weighed by human perception of VL	Lux
Photon flux	The number of photons delivered per unit of surface area at a given time	Photons/meters ² /seconds
Coherence	Light waves have an identical wavelength and constant phase	N/A
Collimation	Light waves are parallel	N/A

e is a mathematical constant with an approximate value of 2.718.

VL, Visible light.

triphosphate (ATP), nitric oxide, and cyclic adenosine monophosphate (cAMP), elicit the modulation of inflammation, proliferation, and tissue repair.²⁸ This process is called photobiomodulation, or low-level light therapy. VL is not known to induce cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts directly because DNA is a primary UVR chromophore.^{4-6,29,30} However, VL generates ROS, which can cause CPDs through a photochemical response.³¹⁻³⁴ Water, which comprises ~15% to 20% of the stratum corneum and ~70% to 75% of the remaining epidermis and dermis, has low VL absorption.^{3,35-39} However, water is the primary chromophore for IR therapy (e.g., CO₂ laser).

Wavelength is directly proportional to the depth of penetration but inversely related to energy, according to Beer-Lambert and Planck’s laws, respectively.^{40,41} Consequently, blue light (BL) is higher energy than red light (RL) but has less penetration. Pathologic skin changes, including edema, erythema, pigmentation, and fibrosis, can alter light

penetration by changing chromophore concentrations and tissue density.³ Along with demonstrating increased penetration depth with increasing wavelength, a custom Monte Carlo simulation of a multi-layered skin model demonstrated that increasing the beamwidth for intense pulsed light (IPL) enhances VL skin penetration.⁴² Monte Carlo computer simulations use skin and light parameters to model depth of penetration.^{43,44} Penetration depth increased markedly as beamwidth increased from 1 to 5 mm.^{42,45} Maximum penetration was achieved with a 10-mm beamwidth, and larger beamwidths did not further increase penetration depth.^{42,45}

Because depth of penetration can vary based on beamwidth, wavelength, and power density, published measurements and simulations of light penetration can vary substantially.^{25,27,46-49} RL penetrates 6 to 50 mm deep.^{25,27,47-50} BL likely has a maximum skin penetration of 0.5 to 1 mm.^{42,51} Epidermal thickness is ~30 to 100 μm and epidermal plus dermal skin thickness is ~0.5 to 6 mm.^{48,52-54}




Fig 2. Diagram of natural and artificial visible light sources. Devices are labeled with significant parts. Collimation (i.e., parallel), coherence (i.e., in-phase), and chromaticity are provided for each light source. **A**, Sunlight is relatively collimated at the surface of the Earth. **B**, Lasers pump energy through a gain medium (e.g., crystal or gas) to generate or amplify light between mirrors in the resonator cavity. The variable attenuator in the resonator cavity of Q-switched lasers allows for beam pulsing. Lasers are highly monochromatic, coherent, and collimated on emission. **C**, Light-emitting diodes (LEDs) pass an electrical current through a semiconductor. LEDs produce light in a narrow range to appear as a single color. Multiple LEDs can be placed in an array to generate white light or higher power densities. **D**, Arc and flash lamps (e.g., intense pulsed light [IPL]) arc electricity through a mercury or xenon gas chamber and are optimized for continuous and pulsed operating conditions, respectively. Filters are applied to achieve specific wavelengths. **E**, Halogen lamps heat a tungsten filament in a sealed chamber with small amounts of halogen gas. **F**, Fluorescent lights excite electricity through mercury gas to produce UVR, which is converted to VL via the phosphorescent coating on the lamp's inner surface.

When administered at the correct settings, VL can likely penetrate entirely through the epidermis. RL can likely reach most, if not all, dermal structures.

SKIN CHROMOPHORES

- Melanin, heme, and opsins are chromophores receptive to VL
- Chromophores have specific absorption spectra
- The biologic effects of VL are mediated through skin chromophores

The primary VL skin chromophores are melanin, heme, and opsin (OPN) photoreceptors.^{3,11,28} Chromophores in the skin absorb discrete wavelengths at varying affinities (i.e., the absorption coefficient). It is possible to target chromophores by selectively using appropriate wavelengths and pulse widths.^{55,56} According to the theory of selective photothermolysis, the pulse width must be shorter than the tissue's thermal relaxation time, or nonspecific thermal tissue damage occurs.⁵⁶

Light energy parameters that do not cause photothermolysis or thermal damage but still alter biologic function are considered photobiomodulatory.^{28,57} Photobiomodulation affects skin according to hormetic paradigms. Hormesis is the principle that an agent, substance, stimulus, or condition can induce a biphasic dose response. The lower fluences of VL can have stimulatory effects, while higher fluences can have inhibitory, cytotoxic, or destructive effects.⁵⁸⁻⁶¹ The skin has an optical wavelength window (600-1300 nm) in which melanin, hemoglobin, and water absorption coefficients are the smallest.^{3,25} Within this optical window, RL and IRA light are absorbed by COX to trigger nonthermal photobiomodulatory effects.⁵⁸⁻⁶¹

Melanin

Human skin melanocytes produce 2 main types of melanin from dihydroxyphenylalanine precursors: yellow-red pheomelanin and black-brown eumelanin.^{62,63} BL, also called high-energy VL, stimulates the expression and activity of tyrosinase, the rate-limiting enzyme in melanin production, via the OPN3 receptor present on keratinocytes and melanocytes.^{64,65} In melanocytes from skin of color (but not from lighter skin types), BL activation of OPN3 leads to tyrosinase/tyrosinase-related protein complex formation.⁶⁵ Therefore, BL may increase melanogenesis.^{64,65}

Melanin has a poorly characterized structure and an absorption spectrum of 200-900 nm.^{3,62,63,66-69} Peak absorption varies depending on the melanin moiety but light absorption is greatest in the UV spectrum and decreases into the VL and IR spectra.^{3,66-69} However, due to melanin's broad absorption spectrum in the VL range, melanosomes may

absorb light intended for other chromophores during phototherapy.⁷⁰ Additionally, melanin has a thermal relaxation period of 70-250 ns.^{3,66-69} Patients with skin of color benefit from laser treatment with picosecond lasers, longer wavelengths, and lower power densities to limit thermal tissue damage.⁷¹⁻⁷³ As a result, near-IR lasers (e.g., 1064 nm Nd:YAG) are considered safer than VL lasers for skin of color and pigmentation.⁷⁴

In melanin-containing cells, ROS and reactive nitrogen species (RNS) generated by VL exposure can cause radiation-independent CPDs.^{34,67,75-77} Radiation-independent CPDs develop 3 hours after UVA exposure and are due to melanin interactions with ROS and RNS.³⁴ In contrast, most CPDs are formed by the direct absorption of UVB by DNA. Potential VL-induced CPDs from ROS and RNS generation have been poorly studied.

Hemoglobin and heme derivatives

Hemoglobin has peak absorptions in the blue (418 nm) and yellow/orange (542 nm/577 nm, respectively) wavebands.^{3,24} The concentration of erythrocytes is the primary determinant of light absorption by hemoglobin.^{3,24} Porphyrins are tetrapyrrole macromolecules that serve as the intermediate for heme.⁷⁸⁻⁸⁰ Accumulation of porphyrins due to enzyme dysfunction causes cutaneous porphyrias. Porphyrins have an absorption spectrum at 400-405 nm, known as the Soret band, with a weaker absorption spectrum of 500-750 nm.^{81,82} During photodynamic therapy (PDT), exogenous aminolevulinic acid is applied to the skin. Aminolevulinic acid, a nonphotosensitive porphyrin precursor, accumulates in cells and is converted to protoporphyrin IX.⁸³ Subsequent irradiation with BL or RL from LEDs, fluorescent lights, or halogen lamps induces ROS generation and cell apoptosis.⁸⁴⁻⁸⁷ PDT, which is commonly used to treat actinic keratosis and skin aging, is considered a nonphotothermolytic process.

COX is a heme and copper-containing protein in the mitochondrial electron transport chain that absorbs RL and IRA.^{28,57} RL and IRA absorption by COX is one of the primary drivers of photobiomodulation.^{28,57} RL and IRA activate the electron transport chain, which increases mitochondrial membrane potential and leads to the intracellular accumulation of second messengers: ATP, ROS, cAMP, Ca²⁺, and nitric oxide.^{28,57} This can alter gene expression, protein activity, redox reactions, inflammation, and metabolism.^{28,30,31,57}

Opsins

OPN photoreceptors absorb specific wavelengths of light and are responsible for VL phototransduction (Table II).⁸⁸⁻⁹⁰ Photoactivation of OPN1 and OPN2 in the retina's cone and rod cells

Table II. Identified skin opsins listed with their associated activation wavelengths, identified expressed skin locations, and cell types

Opsin	Activation wavelength (nm)	Skin expression
OPN1-SW	420-425	Epidermis, melanocytes, keratinocytes, and fibroblasts
OPN1-MW	527-530	Epidermis
OPN1-LW	557-560	Epidermis
OPN2	500-505	Melanocytes, keratinocytes, fibroblasts, and hair follicle stem cells
OPN3	420-527	Melanocytes, keratinocytes, fibroblasts, and hair follicle stem cells
OPN4	480	Fibroblasts
OPN5	380	Melanocytes, keratinocytes, and fibroblasts
Peropsin	380-400	Keratinocytes

nm, Nanometer; OPN, opsin; OPN1-SW, opsin 1, short wave sensitive; OPN1-MW, opsin 1, medium wave sensitive; OPN1-LW, opsin 1, long wave sensitive.

provides visual image signals.^{89,90} Non-image-forming OPNs have been identified in the skin, and these can regulate circadian rhythms, epidermal barrier function, and melanogenesis.^{64,88,91-95} Interaction of BL with OPN3 results in sustained tyrosinase activity in melanocytes from dark-skinned subjects; this interaction may also increase keratinocyte differentiation.^{65,91}

SKIN REACTIONS AND PATHOLOGIES

- VL induces greater hyperpigmentation in skin of color than in light skin
- VL triggers photodermatoses, including cutaneous porphyrias

Hyperpigmentation

Broad-spectrum and discrete VL wavelengths induce pigmentation with synergistic effects when combined with UVA exposure.⁹⁶⁻¹⁰³ Because standard sunscreen may not protect the skin from pure VL and ultraviolet-A1 spectra, recent studies have examined the effects of VL and UVA1 on pigmentation and erythema. Pigmentation lasting at least 2 weeks occurred after broad-spectrum VL irradiation (> 97.5% VL, < 0.2% UVA, 0.8%-2.4% IRA) at 40-80 J/cm² in skin types III-VI.^{97,104,105} Broad-spectrum VL irradiation of 40-80 J/cm² is the equivalent of ~15-30 min of VL solar irradiation.²¹ BL at a fluence of 58 ± 20 J/cm² induced pigmentation in skin types III and IV, persisting at least 21 days.¹⁰⁶ In another study, RL at 320 J/cm² from LEDs induced hyperpigmentation in skin of color subjects, resolving 1 week to 3 months after treatment.⁷⁷ Pigmentation from VL is more intense and sustained than UVA1-induced pigmentation in dark-skinned subjects.^{77,96,97} VL causes a redistribution of melanin from the basal layer to the upper epidermis and the activation of OPN3 in dark-skinned subjects, leading to Ca²⁺ and microphthalmia-associated transcription factor dependent melanogenesis.^{64,65,97,101} Yellow light at

a fluence of 5-20 J/cm² inhibits melanogenesis in vitro.¹⁰⁷

Photodermatoses

Photodermatoses are diseases caused or exacerbated by light. Photodermatoses are classified as immunologically mediated, photoaggravated, or secondary to exogenous/endogenous agents and DNA-repair deficiencies.¹⁰⁸⁻¹¹² UVR is known to be the action spectrum of most photodermatoses. VL is the action spectrum for solar urticaria and cutaneous porphyrias and less commonly for polymorphous (polymorphic) light eruption (PLE) and chronic actinic dermatitis.

Solar urticaria. Solar urticaria is an uncommon mast cell-mediated photodermatosis.^{96,113,114} Symptoms of solar urticaria include erythema, pruritus, and whealing. Phototesting studies indicate that 14% to 90% of patients with solar urticaria reacted to VL alone or in combination with UVR.¹¹⁴⁻¹¹⁷ Fluorescent PDT light sources can induce urticaria and whealing.^{113,118} Phototesting for solar urticaria must be evaluated within minutes after exposure because urticaria resolves within a few hours. Management of solar urticaria includes photoprotection with broad-spectrum sunscreen, antihistamine, UVA/UVA1 hardening, methotrexate, cyclosporine, and omalizumab.¹¹⁹⁻¹²¹ Tinted sunscreen is necessary for individuals with an action spectrum in the VL range.

Porphyrias. Porphyrias are mostly autosomal-dominant diseases caused by the accumulation of porphyrins, which are known phototoxic agents. They are classified as cutaneous (i.e., skin blistering) or neurovisceral (i.e., abdominal pain, vomiting, and tachycardia).^{78,112} Protoporphyrin IX is activated after 10 mW/cm² of BL (405 nm) for 1000 seconds.^{122,123} Management of porphyria cutanea tarda, the most common cutaneous porphyria, includes sun protection, avoidance of exacerbating factors (i.e., alcohol), phlebotomy, and low-dose

chloroquine.^{86,87} In October 2019, the Food and Drug Administration approved afamelanotide (Scenesse), an α -melanocyte-stimulating hormone (α -MSH) analog, as a new treatment for the second most common porphyria in the US, erythropoietic protoporphyria.¹²⁴ Afamelanotide increases melanin production and serves as an antioxidant, hence it down-regulates porphyrin-induced phototoxicity.

Polymorphous (polymorphic) light eruption. PLE is the most common immunologically mediated photodermatosis and has multiple clinical presentations, including vesicular, papular, hemorrhagic, and eczematous. In dark-skinned individuals, it presents as a distinctive pin-head papular eruption.¹²⁵ PLE is the most common photodermatosis worldwide and can affect all races and skin types.¹²⁵ The majority of reactions occur due to UVA alone, but UVB and, uncommonly, VL may be responsible.^{125,126} In 1 study, 100 J/cm² of VL (~40 min of VL sun exposure) induced PLE, compared to 20-35 J/cm² for UVA (~40-75 min of UVR sun exposure).^{21,127} Management of PLE includes photoprotection, antihistamines, and induction of tolerance (i.e., UVB hardening).^{114-117,125}

Chronic actinic dermatitis. Chronic actinic dermatitis presents with eczematous and frequently lichenified skin lesions. UVB, UVA, and rarely VL have been identified as the action spectra, but the most severe reactions are associated with UVB exposure.¹²⁸⁻¹³⁰

Photoexacerbated dermatoses. Exposure to 141 to 313 J/cm² of VL may induce skin reactions in some photoexacerbated dermatoses, including systemic lupus erythematosus.¹³¹

Erythema and inflammation

Subjects with skin phototypes I-III who were exposed to VL with \leq 2% UVA1 immediately developed erythema.¹³² Dark-skinned individuals (phototypes IV-VI) exposed to 480 J/cm² of VL with 0.5% UVA, but not pure VL, immediately developed erythema, as assessed by clinical inspection.¹⁰⁵ In another study of patients with skin types II-IV, VL and UVA1 light elicited immediate erythema lasting less than 24 hours.¹⁰⁴ In 2 randomized controlled trials on the safety of LED RL (633 nm) on human skin, 320 J/cm² and above induced prolonged erythema in some light-skinned patients, while RL at 480 J/cm² and above caused blistering in some patients of various skin types.⁷⁷

Erythema from VL may be due to a combination of inefficient photoenergy transfer in the skin and inflammation and for some light sources, the device's thermal effects might also contribute.^{77,101,133,134} Many laser and light protocols employ cooling

devices to prevent thermal damage and minimize adverse events such as pain, erythema, blistering, scarring, and edema.^{77,135}

PHOTOMEDICAL PHOTOTHERAPY

- For photobiomodulation, light is delivered at parameters that do not induce thermal destructive processes
- Treatment efficacy of VL is wavelength specific for each condition
- Lasers, IPL, LEDs, and fluorescent bulbs are commonly used in VL treatment protocols

Acne

In clinical trials, BL and RL from devices at 400-445 nm and 625-700 nm, respectively, treated mild to moderate acne by decreasing *Cutibacterium acnes* colonization, pore size, and inflammation (Table III).^{17,136-138} Inflammatory lesions may respond better than noninflammatory lesions.^{17,136-139} *C acnes* directly produce porphyrins, which can absorb VL to produce ROS.^{17,138-140} Long-incubation PDT (> 3 hours) with high-intensity RL activation may induce long-term acne remission but is associated with pain, inflammation, and photosensitivity.¹⁴¹

Psoriasis

Narrow-band UVB is commonly used to treat psoriasis, but researchers have also explored using VL.^{17,142} Blue and red LEDs may reduce erythema and improve the local psoriatic severity index.^{17,143,144} VL phototherapy inhibits keratinocyte and endothelial proliferation by increasing cellular differentiation.^{145,146} LED phototherapy may be better suited for reducing psoriatic erythema rather than improving desquamation.^{17,143,144} Psoriasis may recur after treatment ends.

Wound healing

Significant clinical research has examined the use of lasers, IPL, and LEDs for acute and chronic wound healing. Treatment parameters and patient selection vary considerably among publications.^{17,147-149} RL reduces wound healing time, lesion size, and erythema in diabetic foot ulcers.^{17,147-151} Venous ulcers may not respond to photobiomodulation.^{152,153} VL improves wound healing by reducing the expression of proinflammatory proteins and cytokines, increasing OPN3 mediated keratinocyte differentiation and preventing bacterial growth.^{91,154-156}

Hair growth

Multiple devices, including caps, combs, and handheld units, are currently available to stimulate hair growth using LEDs or laser diodes (i.e., lasers

Table III. Therapeutic applications of VL*

Condition	Spectrum	Wavelength (nm)	Device/modality
Acne	Broad	400-700+	IPL
	Blue	405-420	LED
	Blue	405-420	Fluorescent bulb
	Yellow	585 or 595	PDL
	Red	630-670	LED
Hair regrowth	Red	633 or 660	Laser Diode
	Red	630-660	LED
Neonatal jaundice	Blue	450-470	LED
	Blue	400-550	Halogen
	Blue	400-550	Fluorescent
Tattoo removal	Green	532	Frequency-doubled Nd:YAG
	Red	694.3	Ruby
Psoriasis	Blue	405-420	LED
	Yellow	585 or 595	PDL
	Red	625-670	LED
Skin rejuvenation	Yellow	570-590	LED
	Red	625-670	LED
	Red	633 or 660	Laser diode
Vascular lesions	Broad	400-700+	IPL
	Green	532	Frequency-doubled Nd:YAG
	Yellow	578	Copper bromide
	Yellow	585 or 595	PDL
Wound healing	Blue	405-420	LED
	Green	515 or 520	Laser diode
	Yellow	570-590	LED
	Red	625-660	LED
	Red	633 or 660	Laser diode

IPL, Intense pulsed light; LED, light-emitting diode; Nd:YAG, neodymium-doped yttrium aluminum garnet; nm, nanometer; PDL, pulsed dye laser; VL, visible light.

*The efficacy of VL therapy depends on patient selection, disease severity, modality, and device settings.

with a semiconductor gain media). RL increases hair density, growth, and tensile strength in androgenic alopecia by stimulating the anagen growth phase.¹⁵⁷ Clinical studies commonly use RL and near-IR photobiomodulation with fluences of 0.1-150 J/cm² for hair regrowth.^{55,148}

Rejuvenation and photodamage

RL, BL, and yellow light have been studied as antiaging therapeutics.^{17,138} The proposed mechanism of light-mediated antiaging is photobiomodulatory activation of Ca²⁺, nitric oxide, matrix metalloproteinase, and collagen-stimulating pathways.^{17,138} PDT may improve photodamaged facial skin texture, wrinkles, and mottled pigmentation.^{158,159}

PHOTOTHERMOLYTIC PHOTOTHERAPY

- Lasers and IPL target chromophores and induce local tissue destruction via photothermolysis

Vascular lesions

Pulsed dye laser (PDL), range 585-600 nm, targets oxyhemoglobin and is the treatment of choice for

vascular lesions, including port wine stains (PWS), spider angiomas, and hemangiomas.^{3,160-162} In plaque and nail psoriasis, PDL induces photothermolysis of capillaries.^{145,163-167} PDL has been shown to have better efficacy than UVB excimer laser in treating nail bed and matrix lesions.^{145,163-167} Frequency-doubled Nd:YAG (532 nm) are also used for vascular lesions but do not penetrate as deeply as PDL.¹⁶⁰

Special care is recommended when using PDL in skin of color and in infants. The high density of melanin in individuals with skin of color results in the absorption of VL, which generates heat and produces blistering. Asian patients have been safely treated with PDL and IPL for vascular lesions.^{74,168} Infants have thinner and less pigmented skin, and long-pulsed treatment settings are recommended.¹⁶⁹⁻¹⁷²

Tattoo removal. Q-switched frequency-doubled Nd:YAG (532 nm) and ruby (694 nm) lasers are used to remove tattoos.³ Ruby lasers target black and blue pigments, while 532 nm Nd:YAG lasers target yellow, orange, and red pigments. Typically,

black tattoo pigments are easier to remove than colored pigments.¹⁷³ There is enhanced safety and efficacy for tattoo removal using 532 nm picosecond pulsed lasers compared to nanosecond lasers.^{174,175} Common adverse events include immediate erythema, hyper-/hypopigmentation, and hypersensitivity.

FUTURE DIRECTIONS AND CONCLUSION

- VL has the potential to treat a variety of skin diseases and affect skin health
- Additional research is needed to determine the optimal treatment parameters for VL phototherapy

VL is currently used for the treatment of skin conditions and its use may expand to new applications.^{97,132} Skin of color is more susceptible to high fluences of VL and requires conservative treatment parameters. Further research is necessary to determine the functional significance of VL on skin health without confounding UVR and IR wavelengths. A better understanding of VL therapeutic effects would improve treatment protocols and patient care. With the availability of light sources emitting broad but pure VL, these types of studies can now be performed.^{97,132} Comparative clinical trials can elucidate the optimal efficacy of specific wavelengths, fluences, and power densities.

Conflicts of interest

Dr Lim is an investigator for Incyte, L'Oreal, Pfizer, and PCORI, has served as a consultant for Pierre Fabre, ISDIN, Ferndale, Beiersdorf, and La Roche-Posay, and has participated as a speaker in general educational session for La Roche-Posay, and Cantabria labs. Dr Kohli is an investigator (grant funding received by the institution) for Ferndale, Estee Lauder, L'Oreal, Unigen, Johnson and Johnson, Allergan, and Bayer and is a consultant (fee and equipment received by the institution) for Pfizer, Johnson and Johnson, and Bayer. Dr Jagdeo is a member of the GlobalMed Scientific advisory board and a consultant for UV Biotek. Hamzavi is an investigator for Estee Lauder, Ferndale Laboratories, Galderma, Bayer, Loreal, Lenicura, and Unigen. Geisler, Austin, and Nguyen have no conflicts of interest to declare.

REFERENCES

1. Narla S, Kohli I, Hamzavi IH, et al. Visible light in photodermatology. *Photochem Photobiol Sci*. 2020;19(1):99-104.
2. Sowa P, Rutkowska-Talipska J, Rutkowski K, et al. Optical radiation in modern medicine. *Postepy Dermatol Alergol*. 2013;30(4):246-251.
3. Yang MF, Tuchin VV, Yaroslavsky AN. Principles of light-skin interactions. In: Baron E, ed. *Light-Based Therapies for Skin of Color*. Springer-Verlag London; 2009:1-44.
4. Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. *Toxicol Appl Pharmacol*. 2004;195(3):298-308.
5. Alhasaniah A, Sherratt MJ, O'Neill CA. The impact of ultraviolet radiation on barrier function in human skin: molecular mechanisms and topical therapeutics. *Curr Med Chem*. 2018;25(40):5503-5511.
6. Christensen L, Suggs A, Baron E. Ultraviolet photobiology in dermatology. *Adv Exp Med Biol*. 2017;996:89-104.
7. Barolet D, Christiaens F, Hamblin MR. Infrared and skin: friend or foe. *J Photochem Photobiol B*. 2016;155:78-85.
8. Muthusamy V, Piva TJ. The UV response of the skin: a review of the MAPK, NF κ B and TNF α signal transduction pathways. *Arch Dermatol Res*. 2010;302(1):5.
9. Morita A. Current developments in phototherapy for psoriasis. *J Dermatol*. 2018;45(3):287-292.
10. Cho S, Shin MH, Kim YK, et al. Effects of infrared radiation and heat on human skin aging in vivo. *J Invest Dermatol Symp Proc*. 2009;14(1):15-19.
11. Diffey BL. What is light? *Photodermatol Photoimmunol Photomed*. 2002;18(2):68-74.
12. Frederick J, Snell H, Haywood E. Solar ultraviolet radiation at the earth's surface. *Photochem Photobiol*. 1989;50(4):443-450.
13. Diffey BL. Sources and measurement of ultraviolet radiation. *Methods*. 2002;28(1):4-13.
14. Szenicer A, Fouhey DF, Munoz-Jaramillo A, et al. A deep learning virtual instrument for monitoring extreme UV solar spectral irradiance. *Sci Adv*. 2019;5(10):eaaw6548.
15. Yadav RK. Definitions in laser technology. *J Cutan Aesthet Surg*. 2009;2(1):45-46.
16. Farkas JP, Hoopman JE, Kenkel JM. Five parameters you must understand to master control of your laser/light-based devices. *Aesthet Surg J*. 2013;33(7):1059-1064.
17. Jagdeo J, Austin E, Mamalis A, et al. Light-emitting diodes in dermatology: a systematic review of randomized controlled trials. *Lasers Surg Med*. 2018;50(6):613-628.
18. Yuda E, Ogasawara H, Yoshida Y, et al. Suppression of vagal cardiac modulation by blue light in healthy subjects. *J Physiol Anthropol*. 2016;35(1):24.
19. Cuesta M, Boudreau P, Cermakian N, Boivin DB. Skin temperature rhythms in humans respond to changes in the timing of sleep and light. *J Biol Rhythms*. 2017;32(3):257-273.
20. Lok R, van Koningsveld MJ, Gordijn MCM, et al. Daytime melatonin and light independently affect human alertness and body temperature. *J Pineal Res*. 2019;67(1):e12583.
21. Gueymard CA. The sun's total and spectral irradiance for solar energy applications and solar radiation models. *Solar Energy*. 2004;76(4):423-453.
22. Kopp G, Lean JL. A new, lower value of total solar irradiance: evidence and climate significance. *Geophys Res Lett*. 2011;38(1).
23. Ilic S, Leichter S, Streeter J, et al. Effects of power densities, continuous and pulse frequencies, and number of sessions of low-level laser therapy on intact rat brain. *Photomed Laser Surg*. 2006;24(4):458-466.
24. Lister T, Wright PA, Chappell PH. Optical properties of human skin. *J Biomed Opt*. 2012;17(9):090901.
25. Anderson RR, Parrish JA. The optics of human skin. *J Invest Dermatol*. 1981;77(1):13-19.
26. Jacques SL. Optical properties of biological tissues: a review. *Phys Med Biol*. 2013;58(11):R37.
27. Wang EB, Kaur R, Fierro M, et al. Safety and penetration of light into the brain. In: Hamblin M, Huang Y-Y, eds. *Photobiomodulation in the Brain*. Academic Press; 2019:49-66.
28. de Freitas LF, Hamblin MR. Proposed mechanisms of photobiomodulation or low-level light therapy. *IEEE J Sel Top Quantum Electron*. 2016;22(3):7000417.
29. Hoffmann-Dörr S, Greinert R, Volkmer B, et al. Visible light (> 395 nm) causes micronuclei formation in mammalian cells

- without generation of cyclobutane pyrimidine dimers. *Mut Res.* 2005;572(1-2):142-149.
30. Lawrence KP, Douki T, Sarkany RPE, et al. The UV/visible radiation boundary region (385-405 nm) damages skin cells and induces "dark" cyclobutane pyrimidine dimers in human skin in vivo. *Sci Rep.* 2018;8(1):12722.
 31. Liebel F, Kaur S, Ruvolo E, et al. Irradiation of skin with visible light induces reactive oxygen species and matrix-degrading enzymes. *J Invest Dermatol.* 2012;132(7):1901-1907.
 32. Austin E, Huang A, Adar T, et al. Electronic device generated light increases reactive oxygen species in human fibroblasts. *Lasers Surg Med.* 2018. <https://doi.org/10.1002/lsm.22794>.
 33. Mamalis A, Garcha M, Jagdeo J. Light emitting diode-generated blue light modulates fibrosis characteristics: fibroblast proliferation, migration speed, and reactive oxygen species generation. *Lasers Surg Med.* 2015;47(2):210-215.
 34. Premi S, Wallisch S, Mano CM, et al. Photochemistry. Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure. *Science.* 2015;347(6224):842-847.
 35. Lunkenheimer P, Emmert S, Gulich R, et al. Electromagnetic-radiation absorption by water. *Phys Rev E.* 2017;96(6):062607.
 36. Gordon IE, Rothman LS, Gamache RR, et al. Current updates of the water-vapor line list in HITRAN: a new "diet" for air-broadened half-widths. *J Quant Spectrosc Radiat Transf.* 2007;108(3):389-402.
 37. Omi T, Numano K. The role of the CO2 laser and fractional CO2 laser in dermatology. *Laser Ther.* 2014;23(1):49-60.
 38. Nakagawa N, Matsumoto M, Sakai S. In vivo measurement of the water content in the dermis by confocal Raman spectroscopy. *Skin Res Technol.* 2010;16(2):137-141.
 39. Boer M, Duchnik E, Maleszka R, et al. Structural and biophysical characteristics of human skin in maintaining proper epidermal barrier function. *Postepy Dermatol Alergol.* 2016;33(1):1-5.
 40. Kocsis L, Herman P, Eke A. The modified Beer-Lambert law revisited. *Phys Med Biol.* 2006;51(5):N91.
 41. Planck M. On the law of the energy distribution in the normal spectrum. *Ann Phys.* 1901;4(553):1-11.
 42. Ash C, Dubec M, Donne K, et al. Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods. *Lasers Med Sci.* 2017;32(8):1909-1918.
 43. Li T, Xue C, Wang P, et al. Photon penetration depth in human brain for light stimulation and treatment: a realistic Monte Carlo simulation study. *J Innov Opt Health Sci.* 2017;10(05):1743002.
 44. Jarrah I, Radaideh MI, Kozlowski T. Determination and validation of photon energy absorption buildup factor in human tissues using Monte Carlo simulation. *Radiat Phys Chem.* 2019;160:15-25.
 45. Thaysen-Petersen D, Bjerring P, Dierickx C, et al. A systematic review of light-based home-use devices for hair removal and considerations on human safety. *J Eur Acad Dermatol Venereol.* 2012;26(5):545-553.
 46. Lanzafame R. Light dosing and tissue penetration: it is complicated. *Photobiomodul Photomed Laser Surg.* 2020;38(7):393-394.
 47. Hu D, van Zeyl M, Valter K, Potas JR. Sex, but not skin tone affects penetration of red-light (660 nm) through sites susceptible to sports injury in lean live and cadaveric tissues. *J Biophotonics.* 2019;12(7):e201900010.
 48. Salehpour F, Cassano P, Rouhi N, et al. Penetration profiles of visible and near-infrared lasers and light-emitting diode light through the head tissues in animal and human species: a review of literature. *Photobiomodul Photomed Laser Surg.* 2019;37(10):581-595.
 49. Clement M, Daniel G, Trelles M. Optimising the design of a broad-band light source for the treatment of skin. *J Cosmet Laser Ther.* 2005;7(3-4):177-189.
 50. Niu T, Tian Y, Cai Q, et al. Red light combined with blue light irradiation regulates proliferation and apoptosis in skin keratinocytes in combination with low concentrations of curcumin. *PLoS One.* 2015;10(9):e0138754.
 51. Ankrí R, Lubart R, Taitelbaum H. Estimation of the optimal wavelengths for laser-induced wound healing. *Lasers Surg Med.* 2010;42(8):760-764.
 52. Lee Y, Hwang K. Skin thickness of Korean adults. *Surg Radiol Anat.* 2002;24(3-4):183-189.
 53. Oltulu P, Ince B, Kökbudak N. Measurement of epidermis, dermis, and total skin thicknesses from six different body regions with a new ethical histometric technique. *Turk J Plast Surg.* 2018;26:56-61.
 54. Chopra K, Calva D, Sosin M, et al. A comprehensive examination of topographic thickness of skin in the human face. *Aesthet Surg J.* 2015;35(8):1007-1013.
 55. Young AR. Chromophores in human skin. *Phys Med Biol.* 1997;42(5):789-802.
 56. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. *Science.* 1983;220(4596):524-527.
 57. Hamblin MR. Mechanisms and mitochondrial redox signaling in photobiomodulation. *Photochem Photobiol.* 2018;94(2):199-212.
 58. Kuffler DP. Photobiomodulation in promoting wound healing: a review. *Regen Med.* 2016;11(1):107-122.
 59. Huang YY, Sharma SK, Carroll J, et al. Biphasic dose response in low level light therapy: an update. *Dose Response.* 2011;9(4):602-618.
 60. Calabrese EJ. Hormesis: path and progression to significance. *Int J Mol Sci.* 2018;19(10):2871.
 61. Lev-Tov H, Mamalis A, Brody N, et al. Inhibition of fibroblast proliferation in vitro using red light-emitting diodes. *Dermatol Surg.* 2013;39(8):1167-1170.
 62. Micillo R, Panzella L, Koike K, et al. "Fifty shades" of black and red or how carboxyl groups fine tune eumelanin and pheomelanin properties. *Int J Mol Sci.* 2016;17(5):746.
 63. Hunt G, Kyne S, Ito S, et al. Eumelanin and pheomelanin contents of human epidermis and cultured melanocytes. *Pigment Cell Res.* 1995;8(4):202-208.
 64. Setty SR. Opsin3-A link to visible light-induced skin pigmentation. *J Invest Dermatol.* 2018;138(1):13-15.
 65. Regazzetti C, Sormani L, Debayle D, et al. Melanocytes sense blue light and regulate pigmentation through Opsin-3. *J Invest Dermatol.* 2018;138(1):171-178.
 66. Zonios G, Dimou A, Bassukas I, et al. Melanin absorption spectroscopy: new method for noninvasive skin investigation and melanoma detection. *J Biomed Opt.* 2008;13(1):014017.
 67. Brenner M, Hearing VJ. The protective role of melanin against UV damage in human skin. *Photochem Photobiol.* 2008;84(3):539-549.
 68. Ou-Yang H, Stamatas G, Kollias N. Spectral responses of melanin to ultraviolet A irradiation. *J Invest Dermatol.* 2004;122(2):492-496.
 69. Xiao M, Chen W, Li W, et al. Elucidation of the hierarchical structure of natural eumelanins. *J R Soc Interface.* 2018;15(140):20180045.
 70. Jackson BA. Lasers in ethnic skin: a review. *J Am Acad Dermatol.* 2003;48(6):S134-S138.
 71. Shah S, Alster TS. Laser treatment of dark skin: an updated review. *Am J Clin Dermatol.* 2010;11(6):389-397.
 72. Randhawa M, Seo I, Liebel F, et al. Visible light induces melanogenesis in human skin through a photoadaptive response. *PLoS One.* 2015;10(6):e0130949.
 73. Bhatt N, Alster TS. Laser surgery in dark skin. *Dermatol Surg.* 2008;34(2):184-195.

74. Woolery-Lloyd H, Ferguson N. Lasers in skin of color. In: Nouri K, ed. *Lasers in Dermatology and Medicine*. 2nd ed. Springer-Verlag London; 2018:437-448.
75. Cope FW, Sever RJ, Polis BD. Reversible free radical generation in the melanin granules of the eye by visible light. *Arch Biochem Biophys*. 1963;100(2):171-177.
76. Chiarelli-Neto O, Ferreira AS, Martins WK, et al. Melanin photosensitization and the effect of visible light on epithelial cells. *PLoS One*. 2014;9(11):e113266.
77. Jagdeo J, Nguyen JK, Ho D, et al. Safety of light emitting diode-red light on human skin: two randomized controlled trials. *J Biophotonics*. 2020;13(3):e201960014.
78. Schulenburg-Brand D, Katugampola R, Anstey AV, et al. The cutaneous porphyrias. *Dermatol Clin*. 2014;32(3):369-384, ix.
79. Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. *Br J Haematol*. 2017;176(4):527-538.
80. Uttamlal M, Holmes-Smith AS. The excitation wavelength dependent fluorescence of porphyrins. *Chem Phys Lett*. 2008;454(4-6):223-228.
81. Makarska-Bialokoz M. Comparative study of binding interactions between porphyrin systems and aromatic compounds of biological importance by multiple spectroscopic techniques: a review. *Spectrochim Acta A Mol Biomol Spectrosc*. 2018;200:263-274.
82. Giovannetti R. The use of spectrophotometry UV-vis for the study of porphyrins. In: Uddin J, ed. *Macro to Nano Spectroscopy*. 2012;1:87-108.
83. Nielsen KP, Juzeniene A, Juzenas P, et al. Choice of optimal wavelength for PDT: the significance of oxygen depletion. *Photochem Photobiol*. 2005;81(5):1190-1194.
84. LaRochelle EP, Marra K, LeBlanc RE, et al. Modeling PpIX effective light fluence at depths into the skin for PDT dose comparison. *Photodiagnosis Photodyn Ther*. 2019;25:425-435.
85. Austin E, Koo E, Jagdeo J. Thermal photodynamic therapy increases apoptosis and reactive oxygen species generation in cutaneous and mucosal squamous cell carcinoma cells. *Sci Rep*. 2018;8(1):1-9.
86. Koo E, Austin E, Mamalis A, et al. Efficacy of ultra short sub-30 minute incubation of 5-aminolevulinic acid photodynamic therapy in vitro. *Lasers Surg Med*. 2017;49(6):592-598.
87. Koo E, Austin E, Mamalis A, et al. Thermal ultra short photodynamic therapy: heating fibroblasts during sub-30-minute incubation of 5-aminolevulinic acid increases photodynamic therapy-induced cell death. *Dermatol Surg*. 2018;44(4):528-533.
88. Suh S, Choi EH, Atanaskova Mesinkovska N. The expression of opsins in the human skin and its implications for photobiomodulation: a systematic review. *Photodermatol Photoimmunol Photomed*. 2020;36(5):329-338.
89. Terakita A. The opsins. *Genome Biol*. 2005;6(3):213.
90. Olinski LE, Lin EM, Oancea E. Illuminating insights into opsin 3 function in the skin. *Adv Biol Reg*. 2020;75:100668.
91. Castellano-Pellicena I, Uzunbajakava NE, Mignon C, et al. Does blue light restore human epidermal barrier function via activation of Opsin during cutaneous wound healing? *Lasers Surg Med*. 2019;51(4):370-382.
92. Ozdeslik RN, Olinski LE, Trieu MM, et al. Human nonvisual opsin 3 regulates pigmentation of epidermal melanocytes through functional interaction with melanocortin 1 receptor. *Proc Natl Acad Sci U S A*. 2019;116(23):11508-11517.
93. Tsutsumi M, Ikeyama K, Denda S, et al. Expressions of rod and cone photoreceptor-like proteins in human epidermis. *Exp Dermatol*. 2009;18(6):567-570.
94. Lamb TD, Collin SP, Pugh EN. Evolution of the vertebrate eye: opsins, photoreceptors, retina and eye cup. *Nat Rev Neurosci*. 2007;8(12):960-976.
95. Haltaufderhyde K, Ozdeslik RN, Wicks NL, et al. Opsin expression in human epidermal skin. *Photochem Photobiol*. 2015;91(1):117-123.
96. Mahmoud BH, Hessel CL, Hamzavi IH, et al. Effects of visible light on the skin. *Photochem Photobiol*. 2008;84(2):450-462.
97. Mahmoud BH, Ruvolo E, Hessel CL, et al. Impact of long-wavelength UVA and visible light on melanocompetent skin. *J Invest Dermatol*. 2010;130(8):2092-2097.
98. Kollias N, Baqer A. An experimental study of the changes in pigmentation in human skin in vivo with visible and near infrared light. *Photochem Photobiol*. 1984;39(5):651-659.
99. Rosen CF, Jacques SL, Stuart ME, et al. Immediate pigment darkening: visual and reflectance spectrophotometric analysis of action spectrum. *Photochem Photobiol*. 1990;51(5):583-588.
100. Ramasubramaniam R, Roy A, Sharma B, et al. Are there mechanistic differences between ultraviolet and visible radiation induced skin pigmentation? *Photochem Photobiol Sci*. 2011;10(12):1887-1893.
101. Sklar LR, Almutawa F, Lim HW, et al. Effects of ultraviolet radiation, visible light, and infrared radiation on erythema and pigmentation: a review. *Photochem Photobiol Sci*. 2013;12(1):54-64.
102. Porges SB, Kaidbey KH, Grove GL. Quantification of visible light-induced melanogenesis in human skin. *Photodermatol*. 1988;5(5):197-200.
103. Cohen L, Brodsky MA, Zubair R, et al. Cutaneous interaction with visible light: what do we know. *J Am Acad Dermatol*. 2020. <https://doi.org/10.1016/j.jaad.2020.03.115>.
104. Soleymani T, Cohen DE, Folan LM, et al. Disparity in cutaneous pigmentary response to LED vs halogen incandescent visible light: results from a single center, investigational clinical trial determining a minimal pigmentary visible light dose. *J Drugs Dermatol*. 2017;16(11):1105-1110.
105. Kohli I, Braunberger TL, Nahhas AF, et al. Long-wavelength ultraviolet A1 and visible light photoprotection: a multimodality assessment of dose and response. *Photochem Photobiol*. 2020;96(1):208-214.
106. Duteil L, Cardot-Leccia N, Queille-Roussel C, et al. Differences in visible light-induced pigmentation according to wavelengths: a clinical and histological study in comparison with UVB exposure. *Pigment Cell Melanoma Res*. 2014;27(5):822-826.
107. Chen L, Xu Z, Jiang M, Zhang C, Wang X, Xiang L. Light-emitting diode 585nm photomodulation inhibiting melanin synthesis and inducing autophagy in human melanocytes. *J Dermatol Sci*. 2018;89(1):11-18.
108. Alvarez MS, Jacobs S, Jiang SB, et al. Photocontact allergy to diallyl disulfide. *Am J Contact Dermatitis*. 2003;14(3):161-165.
109. Morikawa F, Fukuda M, Naganuma M, et al. Phototoxic reaction to xanthene dyes induced by visible light. *J Dermatol*. 1976;3(2):59-67.
110. Cotterill JA. Severe phototoxic reaction to laser treatment in a patient taking St John's Wort. *J Cosmet Laser Ther*. 2001;3(3):159-160.
111. Lehmann P, Schwarz T. Photodermatoses: diagnosis and treatment. *Dtsch Arztebl Int*. 2011;108(9):135-141.
112. Dawe R. An overview of the cutaneous porphyrias. *F1000Res*. 2017;6:1906.
113. Goetze S, Elsner P. Solar urticaria. *J Dtsch Dermatol Ges*. 2015;13(12):1250-1253.
114. Kishimoto I, Uetsu N, Tanimura H, et al. Solar urticaria with a wide action spectrum from UVB to visible light complicated with UVA-induced polymorphous light eruption. *Photodermatol Photoimmunol Photomed*. 2017;33(3):172-175.
115. Pérez-Ferriols A, Barnadas M, Gardeazabal J, et al. Solar urticaria: epidemiology and clinical phenotypes in a Spanish series of 224 patients. *Actas Dermosifiliogr*. 2017;108(2):132-139.

116. Silpa-archa N, Wongpraparut C, Leenutaphong V. Analysis of solar urticaria in Thai patients. *Asian Pac J Allergy Immunol.* 2016;34(2):146-152.
117. Monfrecola G, Masturzo E, Riccardo AM, et al. Solar urticaria: a report on 57 cases. *Am J Contact Derm.* 2000;11(2):89-94.
118. Yokoyama S, Nakano H, Nishizawa A, et al. A case of photo-contact urticaria induced by photodynamic therapy with topical 5-aminolaevulinic acid. *J Dermatol.* 2005;32(10):843-847.
119. Pinto Gouveia M, Gameiro A, Pinho A, et al. Long-term management of chronic spontaneous urticaria with omalizumab. *Clin Exp Dermatol.* 2017;42(7):735-742.
120. Harris BW, Badri T, Schlessinger J. Solar Urticaria. In: *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; 2021. Accessed March 10, 2021. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK441986/>
121. Jiang AJ, Lim HW. Phototherapy in the evaluation and management of photodermatoses. *Dermatol Clin.* 2020;38(1):71-77.
122. Willey A, Anderson RR, Sakamoto FH. Temperature-modulated photodynamic therapy for the treatment of actinic keratosis on the extremities: a pilot study. *Dermatol Surg.* 2014;40(10):1094-1102.
123. Maytin EV, Kaw U, Ilyas M, et al. Blue light versus red light for photodynamic therapy of basal cell carcinoma in patients with Gorlin syndrome: a bilaterally controlled comparison study. *Photodiagnosis Photodyn Ther.* 2018;22:7-13.
124. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. *N Engl J Med.* 2015;373(1):48-59.
125. Artz CE, Farmer CM, Lim HW. Polymorphous light eruption: a review. *Curr Dermatol Rep.* 2019;8(3):110-116.
126. van de Pas CB, Hawk JL, Young AR, et al. An optimal method for experimental provocation of polymorphic light eruption. *Arch Dermatol.* 2004;140(3):286-292.
127. Boonstra HE, van Weelden H, Toonstra J, et al. Polymorphous light eruption: a clinical, photobiologic, and follow-up study of 110 patients. *J Am Acad Dermatol.* 2000;42(2 Pt 1):199-207.
128. Quatrano NA, Shvartsbeyn M, Meehan SA, et al. Chronic actinic dermatitis occurring in an adult with atopic dermatitis. *Dermatol Online J.* 2015;21(12).
129. Lim HW, Morison WL, Kamide R, et al. Chronic actinic dermatitis. An analysis of 51 patients evaluated in the United States and Japan. *Arch Dermatol.* 1994;130(10):1284-1289.
130. Healy E, Rogers S. Photosensitivity dermatitis/actinic reticuloid syndrome in an Irish population: a review and some unusual features. *Acta Derm Venereol.* 1995;75(1):72-74.
131. van Weelden H, Velthuis PJ, Baart de la Faille H. Light-induced skin lesions in lupus erythematosus: photobiological studies. *Arch Dermatol Res.* 1989;281(7):470-474.
132. Kohli I, Zubair R, Lyons AB, et al. Impact of long-wavelength ultraviolet A1 and visible light on light-skinned individuals. *Photochem Photobiol.* 2019;95(6):1285-1287.
133. Nardelli A, Deuschle E, de Azevedo LD, et al. Assessment of light emitting diodes technology for general lighting: a critical review. *Renew Sust Energy Rev.* 2017;75:368-379.
134. Polefka TG, Meyer TA, Agin PP, et al. Effects of solar radiation on the skin. *J Cosmet Dermatol.* 2012;11(2):134-143.
135. Das A, Sarda A, De A. Cooling devices in laser therapy. *J Cutan Aesthet Surg.* 2016;9(4):215-219.
136. Platsidaki E, Dessinioti C. Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. *F1000Res.* 2018;7:1953.
137. Scholz CFP, Kilian M. The natural history of cutaneous propionibacteria, and reclassification of selected species within the genus Propionibacterium to the proposed novel genera Acidipropionibacterium gen. nov., Cutibacterium gen. nov. and Pseudopropionibacterium gen. nov. *Int J Syst Evol Microbiol.* 2016;66(11):4422-4432.
138. Greaves AJ. The effects of narrowbands of visible light upon some skin disorders: a review. *Int J Cosmet Sci.* 2016;38(4):325-345.
139. Handler MZ, Bloom BS, Goldberg DJ. Energy-based devices in treatment of acne vulgaris. *Dermatol Surg.* 2016;42(5):573-585.
140. Patwardhan SV, Richter C, Vogt A, Blume-Peytavi U, Canfield D, Kottner J. Measuring acne using Coproporphyrin III, Protoporphyrin IX, and lesion-specific inflammation: an exploratory study. *Arch Dermatol Res.* 2017;309(3):159-167.
141. Sakamoto FH, Torezan L, Anderson RR. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice. Part II. Understanding parameters for acne treatment with photodynamic therapy. *J Am Acad Dermatol.* 2010;63(2):195-211.
142. Zhang P, Wu MX. A clinical review of phototherapy for psoriasis. *Lasers Med Sci.* 2018;33(1):173-180.
143. Pfaff S, Liebmann J, Born M, Merk HF, Von Felbert V. Prospective randomized long-term study on the efficacy and safety of UV-free blue light for treating mild psoriasis vulgaris. *Dermatology.* 2015;231(1):24-34.
144. Ho D, Koo E, Mamalis A, et al. A systematic review of light emitting diode (LED) phototherapy for treatment of psoriasis: an emerging therapeutic modality. *J Drugs Dermatol.* 2017;16(5):482-488.
145. Kemény L, Varga E, Novak Z. Advances in phototherapy for psoriasis and atopic dermatitis. *Expert Rev Clin Immunol.* 2019;15(11):1205-1214.
146. Liebmann J, Born M, Kolb-Bachofen V. Blue-light irradiation regulates proliferation and differentiation in human skin cells. *J Invest Dermatol.* 2010;130(1):259-269.
147. França CM, Anders JJ, Lanzafame RJ. Photobiomodulation in Wound healing: what are we not considering? *Photomed Laser Surg.* 2016;34(2):51-52.
148. Mignon C, Botchkareva NV, Uzunbajakava NE, et al. Photobiomodulation devices for hair regrowth and wound healing: a therapy full of promise but a literature full of confusion. *Exp Dermatol.* 2016;25(10):745-749.
149. Tchanque-Fossuo CN, Ho D, Dahle SE, et al. A systematic review of low-level light therapy for treatment of diabetic foot ulcer. *Wound Repair Regen.* 2016;24(2):418-426.
150. Maiya AG, Kumar AS, Hazari A, et al. Photobiomodulation therapy in neuroischaemic diabetic foot ulcers: a novel method of limb salvage. *J Wound Care.* 2018;27(12):837-842.
151. Dos Santos Mendes-Costa L, de Lima VG, Barbosa MPR, et al. Photobiomodulation: systematic review and meta-analysis of the most used parameters in the resolution diabetic foot ulcers. *Lasers Med Sci.* 2020. <https://doi.org/10.1007/s10103-020-03192-y>. [Epub ahead of print].
152. Siqueira CPCM, de Paula Ramos S, Gobbi CA, et al. Effects of weekly LED therapy at 625 nm on the treatment of chronic lower ulcers. *Lasers Med Sci.* 2015;30(1):367-373.
153. Vitse J, Bekara F, Byun S, et al. A double-blind, placebo-controlled randomized evaluation of the effect of low-level laser therapy on venous leg ulcers. *Int J Low Extrem Wounds.* 2017;16(1):29-35.
154. Lipovsky A, Nitzan Y, Gedanken A, et al. Visible light-induced killing of bacteria as a function of wavelength: implication for wound healing. *Lasers Surg Med.* 2010;42(6):467-472.
155. Taradaj J, Shay B, Dymarek R, et al. Effect of laser therapy on expression of angio- and fibrogenic factors, and cytokine concentrations during the healing process of human pressure ulcers. *Int J Med Sci.* 2018;15(11):1105-1112.

156. Yang P, Wang N, Wang C, et al. 460nm visible light irradiation eradicates MRSA via inducing prophage activation. *J Photochem Photobiol B*. 2017;166:311-322.
157. Hamblin MR. Photobiomodulation for the management of alopecia: mechanisms of action, patient selection and perspectives. *Clin Cosmet Investig Dermatol*. 2019;12:669-678.
158. Sanclemente G, Ruiz-Cañas V, Miranda JM, et al. Photodynamic therapy interventions in facial photodamage: a systematic review. *Actas Dermosifiliogr*. 2018;109(3):218-229.
159. Huang A, Nguyen JK, Jagdeo J. Light-emitting diode-based photodynamic therapy for photoaging, scars, and dyspigmentation: a systematic review. *Dermatol Surg*. 2020;46(11):1388-1394.
160. Joo J, Michael D, Kilmer S. Lasers for treatment of vascular lesions. In: Nouri K, ed. *Lasers in Dermatology and Medicine*. 2nd ed. Springer-Verlag London; 2018:49-61.
161. Chang YC, Lee SJ, Chung HJ. Treatment of post-pulsed dye laser purpura with pulsed dye laser. *J Cosmet Laser Ther*. 2018;20(1):21-23.
162. Brauer JA, Farhadian JA, Bernstein LJ, et al. Pulsed dye laser at subpurpuric settings for the treatment of pulsed dye laser-induced ecchymoses in patients with port-wine stains. *Dermatol Surg*. 2018;44(2):220-226.
163. de Leeuw J, van Lingen RG, Both H, et al. A comparative study on the efficacy of treatment with 585 nm pulsed dye laser and ultraviolet B-TL01 in plaque type psoriasis. *Dermatol Surg*. 2009;35(1):80-91.
164. Taibjee S, Cheung ST, Laube S, et al. Controlled study of excimer and pulsed dye lasers in the treatment of psoriasis. *Br J Dermatol*. 2005;153(5):960-966.
165. Al-Mutairi N, Noor T, Al-Haddad A. Single blinded left-to-right comparison study of excimer laser versus pulsed dye laser for the treatment of nail psoriasis. *Dermatol Ther (Heidelb)*. 2014;4(2):197-205.
166. Treewittayapoom C, Singvahanont P, Chanprapaph K, et al. The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, double-blind, inpatient left-to-right study. *J Am Acad Dermatol*. 2012;66(5):807-812.
167. Oram Y, Karıncaoğlu Y, Koyuncu E, et al. Pulsed dye laser in the treatment of nail psoriasis. *Dermatol Surg*. 2010;36(3):377-381.
168. Lin MY, Lin CS, Hu S, et al. The application of 595-nm pulsed dye laser for vascular anomalies in a Chinese population: a 10-year experience. *J Cosmet Laser Ther*. 2019;21(3):171-178.
169. Alegre-Sánchez A, Pérez-García B, Boixeda P. Pulsed-dye laser treatment of port-wine stains in children: useful tips to avoid general anesthesia. *Pediatr Dermatol*. 2017;34(5):619-621.
170. Rizzo C, Brightman L, Chapas AM, et al. Outcomes of childhood hemangiomas treated with the pulsed-dye laser with dynamic cooling: a retrospective chart analysis. *Dermatol Surg*. 2009;35(12):1947-1954.
171. Chinnadurai S, Sathe NA, Surawicz T. Laser treatment of infantile hemangioma: a systematic review. *Lasers Surg Med*. 2016;48(3):221-233.
172. Chapas AM, Eickhorst K, Geronemus RG. Efficacy of early treatment of facial port wine stains in newborns: a review of 49 cases. *Lasers Surg Med*. 2007;39(7):563-568.
173. Torbeck RL, Schilling L, Khorasani H, Dover JS, Arndt KA, Saedi N. Evolution of the picosecond laser: a review of literature. *Dermatol Surg*. 2019;45(2):183-194.
174. Chaowattanapanit S, Silpa-Archa N, Kohli I, et al. Post-inflammatory hyperpigmentation: a comprehensive overview: treatment options and prevention. *J Am Acad Dermatol*. 2017;77(4):607-621.
175. Tafazzoli A, Rostan EF, Goldman MP. Q-switched ruby laser treatment for postsclerotherapy hyperpigmentation. *Dermatol Surg*. 2000;26(7):653-656.

Answers to CME examination

Identification No. JA0521

May 2021 issue of the Journal of the American Academy of Dermatology.

Austin E, Geisler AN, Nguyen J, Kohli I, Hamzavi I, Lim HW, Jagdeo J. *J Am Acad Dermatol* 2021;84:1219-31.

1. b
2. b

3. a
4. d